Next Article in Journal
Evaluation of the Organotellurium Compound AS101 for Treating Colistin- and Carbapenem-Resistant Klebsiella pneumoniae
Next Article in Special Issue
An Experimental Medicine Investigation of the Effects of Subacute Pramipexole Treatment on Emotional Information Processing in Healthy Volunteers
Previous Article in Journal
Chirality-Dependent Anti-Inflammatory Effect of Glutathione after Spinal Cord Injury in an Animal Model
Previous Article in Special Issue
Electroconvulsive Therapy and Age: Effectiveness, Safety and Tolerability in the Treatment of Major Depression among Patients under and over 65 Years of Age
Review

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review

Department and Clinic of Psychiatry, Medical University of Silesia, 42-612 Tarnowskie Góry, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Marek Krzystanek
Pharmaceuticals 2021, 14(8), 793; https://doi.org/10.3390/ph14080793
Received: 28 July 2021 / Revised: 6 August 2021 / Accepted: 11 August 2021 / Published: 12 August 2021
(This article belongs to the Special Issue Affective Disorders Psychopharmacology)
Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this study was to evaluate the efficiency of LSD, psilocybin and DMT in depression treatment in the light of current medical literature. The authors followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines for this systematic review. The authors searched the PubMed and Cochrane Library databases to identify relevant publications. Finally, 10 papers were included. Most of the selected studies showed significant correlation between psilocybin and DMT use and reduction in depression symptom intensity. By analyzing qualified studies, it can be concluded that psilocybin and DMT could be useful in depression treatment, but further observations are still required. View Full-Text
Keywords: lysergic acid diethylamide (LSD); psilocybin; dimethyltryptamine (DMT); depression lysergic acid diethylamide (LSD); psilocybin; dimethyltryptamine (DMT); depression
Show Figures

Figure 1

MDPI and ACS Style

Więckiewicz, G.; Stokłosa, I.; Piegza, M.; Gorczyca, P.; Pudlo, R. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals 2021, 14, 793. https://doi.org/10.3390/ph14080793

AMA Style

Więckiewicz G, Stokłosa I, Piegza M, Gorczyca P, Pudlo R. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals. 2021; 14(8):793. https://doi.org/10.3390/ph14080793

Chicago/Turabian Style

Więckiewicz, Gniewko, Iga Stokłosa, Magdalena Piegza, Piotr Gorczyca, and Robert Pudlo. 2021. "Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review" Pharmaceuticals 14, no. 8: 793. https://doi.org/10.3390/ph14080793

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop